Johnson & Johnson (NYSE:JNJ) CAO Ronald A. Kapusta sold 8,441 shares of the business’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the transaction, the chief accounting officer now owns 17,284 shares of the company’s stock, valued at $2,508,772.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
NYSE:JNJ traded up $0.04 during midday trading on Friday, hitting $145.34. The company had a trading volume of 5,343,128 shares, compared to its average volume of 7,006,641. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The firm has a market capitalization of $382.50 billion, a PE ratio of 19.91, a price-to-earnings-growth ratio of 2.23 and a beta of 0.58. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company had revenue of $20.35 billion during the quarter, compared to analyst estimates of $20.05 billion. During the same period in the previous year, the business earned $1.90 earnings per share. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 8.16 EPS for the current fiscal year.
JNJ has been the subject of a number of recent analyst reports. Raymond James boosted their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Citigroup upped their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research report on Monday, October 22nd. Finally, ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $142.54.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Financial Gravity Wealth Inc. bought a new position in shares of Johnson & Johnson during the first quarter valued at about $105,000. Selective Wealth Management bought a new position in shares of Johnson & Johnson during the third quarter valued at about $105,000. CSat Investment Advisory L.P. bought a new position in shares of Johnson & Johnson during the second quarter valued at about $107,000. WP Advisors LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at about $108,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at about $117,000. Institutional investors and hedge funds own 66.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Ronald A. Kapusta Sells 8,441 Shares of Johnson & Johnson (JNJ) Stock” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://sportsperspectives.com/2018/11/09/ronald-a-kapusta-sells-8441-shares-of-johnson-johnson-jnj-stock.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Diversification For Individual Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.